It may be reasonable to perform targeted exome sequencing or Sanger sequencing of PKD1 and PKD2 to define pathogenic mutations in well-known clinical phenotypes such as ADPKD. The gene discussed is PKD2; the disease is autosomal dominant polycystic kidney disease.